Nature Communications (Mar 2021)
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
- Dimitra Georgopoulou,
- Maurizio Callari,
- Oscar M. Rueda,
- Abigail Shea,
- Alistair Martin,
- Agnese Giovannetti,
- Fatime Qosaj,
- Ali Dariush,
- Suet-Feung Chin,
- Larissa S. Carnevalli,
- Elena Provenzano,
- Wendy Greenwood,
- Giulia Lerda,
- Elham Esmaeilishirazifard,
- Martin O’Reilly,
- Violeta Serra,
- Dario Bressan,
- IMAXT Consortium,
- Gordon B. Mills,
- H. Raza Ali,
- Sabina S. Cosulich,
- Gregory J. Hannon,
- Alejandra Bruna,
- Carlos Caldas
Affiliations
- Dimitra Georgopoulou
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Maurizio Callari
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Oscar M. Rueda
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Abigail Shea
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Alistair Martin
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Agnese Giovannetti
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Fatime Qosaj
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Ali Dariush
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Suet-Feung Chin
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Larissa S. Carnevalli
- Bioscience, Oncology, Early Oncology R&D, AstraZeneca
- Elena Provenzano
- Breast Cancer Programme, CRUK Cambridge Centre
- Wendy Greenwood
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Giulia Lerda
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Elham Esmaeilishirazifard
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Martin O’Reilly
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Violeta Serra
- Experimental Therapeutics Group, Vall d’Hebron Institut d’Oncologia
- Dario Bressan
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- IMAXT Consortium
- Gordon B. Mills
- Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health & Sciences University
- H. Raza Ali
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Sabina S. Cosulich
- Bioscience, Oncology, Early Oncology R&D, AstraZeneca
- Gregory J. Hannon
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Alejandra Bruna
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- Carlos Caldas
- Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge
- DOI
- https://doi.org/10.1038/s41467-021-22303-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
The heterogeneity of breast cancer has a major role in drug response and resistance. In this study, the authors use patient-derived tumour xenografts as a platform for drug testing and correlation with single-cell proteomic phenotypes characterized by mass cytometry.
